{"id":1728,"date":"2015-03-28T08:05:19","date_gmt":"2015-03-28T08:05:19","guid":{"rendered":"http:\/\/biomedpharmajournal.org\/?p=1728"},"modified":"2017-01-04T07:08:37","modified_gmt":"2017-01-04T07:08:37","slug":"a-systematic-review-of-pharmacological-therapies-for-sickle-cell-disease","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol4no1\/a-systematic-review-of-pharmacological-therapies-for-sickle-cell-disease\/","title":{"rendered":"A Systematic Review of Pharmacological Therapies for Sickle Cell Disease"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

Human genetic diversity poses a great challenge to community health care in India. Although many diseases present varied level of complexity, haemoglobin disorders constitute the most common genetic and public health burden on people1<\/sup>. Sickle cell disease (SCD) a common genetic haemoglobin disorder has been reported worldwide. Amino acid substitution that causes SCD is a mutation of the sixth amino acid from glutamic acid to valine2<\/sup>. Inheritance of mutant haemoglobin genes from both parents results into SCD. So far many studies3<\/sup> aimed at determining the prevalence estimates of SCD. However, a comprehensive and reliable data for India context is not available. SCD disorder is largely ignored in many parts of the world including India, though the techniques for diagnosis of the disorder are well known, its treatment has limited scope. Also, it is not a public health priority in many countries where it is prevalent. Furthermore, in countries where SCD is prevalent, health systems are often strained and the main hurdle for management of the SCD sufferers is the lack of resources and understanding of the disorder, which results in increased severity of the condition and drastically shortens life of the affected individual. Majority of children die undiagnosed, untreated or undertreated4<\/sup>.<\/p>\n

The current global economic activity and the relatively newer phenomenon of global migration for work have presented an entirely new aspect to the SCD research. For most healthcare professionals (haematologists), such issues may look far different from regular practice. However, as genetic diseases are increasingly recognized as a major global health problem, haematologists are needed to be equipped with adequate knowledge for dealing with a new spectrum of SCD, which they need to be able to identify and manage.<\/p>\n

Numerous studies5<\/sup> confirmed that early diagnosis and treatment of newborns can reduce many complications and increase life expectancy and quality of life of an SCD patient. Furthermore, Regular blood tests along with prenatal counselling also reduce the number of births of SCD affected children6<\/sup>. There are promising techniques such as solubility test, full blood count, haemoglobin electrophoresis, isoelectric focussing, high performance liquid chromatography, DNA analysis, prenatal diagnosis, chorionic villus sampling, amniocentesis and fetal blood sampling etc. which support in diagnosis of SCD and thereby help in managing and improving SCD patients\u2019 quality of life. Apart from this, now a day\u2019s people are using alternative therapy for SCD management. Medicinal plants have been a source of succour in the control of many diseases and SCD is one of them. Local people from Africa and Asia with high incidence of the SCD have learnt to manage the problem by using plants which have medicinal properties.\u00a0 In Nigeria and most parts of developing countries, medicinal plants have been used in the treatment of painful crises associated with SCD, especially among the lower socio-economic class who cannot afford the high cost of medicine. In the backdrop of the above information, this article attempts to review pharmacological therapies for SCD treatment and other related aspects.<\/p>\n

A survey was conducted7<\/sup> in Lubumbashi city (Democratic Republic of Congo) in order to identify medicinal plants used by traditional healers \u00a0 in the management of SCD. Authors used the Emmel test in vitro, for the antisickling activity assays of aqueous and ethanolic extracts of different parts of these plants. The survey revealed that 13 medicinal plants were used in the treatment of drepanocytosis among which 12 plants exhibited the in vitro antisickling activity for at least one of the used parts or extracts. These plants are Bombax pentadrum, Bougainvillea sp., Byarsocarpus orientalis, Dalberigia bochmintaub, Diplorrhynbchus condolocarpus, Euphorbia heterophylla, Ficus capensis, Harungana madagascariensis, Parinari mobola, Pothmania witfchidii, Syzygium guineense, Temnocalys verdickii and Ziziphus mucronata of which four (Bombax pentadrum, Ficus capensis, Parinari mobola and Ziziphus mucronata) revealed a high antisickling activity. The authors concluded that in vitro Antisickling activity justifies the use of these plants by traditional healers and this activity would be due to anthocyanins.<\/p>\n

The author8<\/sup> studied the role of Cajanus cajan methanolic extract in inhibition of sickling and suggested that the additive antisickling effect of both compounds (phenylalanine and p-hydroxybenzoic acid) can be therapeutically exploited for the treatment of SCD. The leaves of Hymenocardia acida are commonly used alone or in combination with other plant parts to manage SCD9<\/sup>. They found that the antisickling activity was dose dependent. The fractions containing flavonoids, saponins and carboxylic acids were found to be responsible for reversal of the sickled RBC. The anti-sickling activities of the extracts of the roots of a plant Cissus populnea L. (CPK) was examined in one of the study and reported10<\/sup> that extract showed presence of anthraquinone derivatives, steroidal glycosides and cardiac glycosides. The chloroform and water partitioned fractions of the cold methanol extracts of CPK exhibited a 62.2% and 52.9% inhibition of sickling, respectively, at 180 min.<\/p>\n

Pathophysiology and Medical <\/strong>Complications<\/strong><\/p>\n

Pathophysiology is the study of the changes of normal,\u00a0mechanical,\u00a0physical, and\u00a0biochemical\u00a0functions, either caused by a\u00a0disease or resulting from an abnormal syndrome is of utmost importance in case of SCD. Pathophysiological changes observed in the patients with SCD are reported in many studies11<\/sup>. For example, confirmatory studies12<\/sup>revealed that SCD is a genetic disorder of blood which produces abnormal Hb and causes vasoocclusion as well as the disruption of oxygen to body tissues, because of which innumerable SCD patients suffer from other medical complications that include but are not limited to delayed growth and delayed sexual maturation; acute chest syndrome, priapism, stroke, Dactylitis, Renal Disease, sickle cell retinopathy, dermal ulcers, severe chronic pain and oxygen etc. These were the major clinical reasons for hospitalization as well as death in some cases. The authors advocate the need for management of patients with SCD with a multi-disciplinary approach13<\/sup>.<\/p>\n

Role of Antioxidants<\/strong><\/p>\n

Studies14<\/sup>carried out in Central India reported lower vitamin E levels in SCD patients. Homozygous SCD had lower levels of all three vitamins, such as vitamin E, vitamin C and beta-carotene levels. Significant depletion of the antioxidant vitamins, particularly in severe forms of SCD has also been reported indicating the necessity to provide appropriate food supplements and medication.<\/p>\n

Oxidative phenomena play a significant role in the SCD’s pathophysiology15<\/sup>. They evaluated the antioxidant effect of garlic (Allium sativum), AGE on sickle red blood cells. Their study data suggest that AGE has a significant antioxidant activity on sickle RBCs, which may be further evaluated as a potential therapeutic agent to ameliorate complications of SCD.<\/p>\n

Another study reported16<\/sup> that certain erythrocytes with an elevated density are believed to be the root of the painful crisis and anemia of the patients. On the basis of in vivo and ex vivo studies, the authors proposed that a cocktail of antioxidants would have beneficial effects in lessening the incidence and severity of crisis and reducing anemia in SCD.<\/p>\n

Fetal haemoglobin<\/strong><\/p>\n

The newborn infant is protected by the high level of fetal hemoglobin in the red cells during the first 8 to 10 weeks of life. As the level declines the clinical manifestations of sickle cell disease appear, and the hematologic manifestations of SCD are apparent by 10 to 12 weeks of age17<\/sup>. High level of fetal Hb in the red cells, which persists during the first year of life, somehow protects the infant. In view of this, it is obvious that the infants should be screened at appropriate time to determine the clinical complications.<\/p>\n

Physical growth<\/strong><\/p>\n

It\u2019s a common clinical feature of SCD (SS pattern) is reported18,19<\/sup> as poor growth, weigh less, shorter and poor nutritional status in combination with delayed sexual and skeletal maturation. The nature and magnitude of body-compartment shortage are important in understanding the nutritional needs of children with SCD and for monitoring the outcomes of nutrition interventions. Children with SCD have impaired growth, delayed puberty, and poor nutritional status. Body-composition abnormalities suggested the nutritional need.<\/p>\n

Iron Deficiency Anaemia<\/strong><\/p>\n

Earlier study20 <\/sup>documented the Iron Deficiency Anaemia (IDA) in Indian population. Furthermore, another past study21<\/sup> reported that children with IDA show significantly higher red blood cell counts and higher total iron binding capacity but significantly (P<0.05) lower reticulocyte counts than children without IDA22<\/sup>, which clearly indicated that IDA is a clinical problem of children with SCD.<\/p>\n

The oral administration of aqueous extract of Sorghum bicolor (L.) Moench stem bark administration produced significant increase in haemoglobin, packed cell volume and red blood cells in iron sufficient and iron deficient groups (P < 0.05)23<\/sup>. The results revealed that extract administration has restored the anaemic condition in the iron deficient group and thus presents credence to its use as a medicine in the management of anaemia. Wild plant Pfaffia Paniculata (PP) functions as a sodium ionophore on sickle cells and improves their hydration status and rheological properties24<\/sup>. Author further noticed that the PP Improves the deformability of sickle cell, as well as it increases sodium content and mean corpuscular volume (MCV).<\/p>\n

Pain<\/strong><\/p>\n

Acute episodes of pain have been extensively reported25 <\/sup>in SCD patients. Patients who had more pain episodes tend to die early, which could be because of high Hematocrit and low Hb F level. From these observations, it may be noted that pain rate correlates with early death in SCD. Hence prevention of pain episodes is necessary to increase the life span of SCD patients. Management of pain associated with SCD consists of the use of nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvant medications26<\/sup>. However, to improve the quality of life, the medical professionals should be sensitized regularly regarding the therapeutic developments for combating the pain crises. Author supported27<\/sup> the decision of pharmacological screening of siculine syrup (a traditional herbal remedy purported to be useful in the prevention and treatment of sickle cell pain \u2013 crises), which has antisickling and analgesic activities as well as antimicrobial and diuretic effects. The author reported that siculine syrup is used by the local population of Nigeria for the prevention and treatment of sickle cell pain crises.<\/p>\n

Leg ulcer<\/strong><\/p>\n

The ulcers usually appear between ages 10 and 50 years and are seen more frequently in males than in females28<\/sup>. It has been reported29<\/sup> that often decreased oxygen capacity in the blood results in the leg ulcer complications in SCD patients, where anti sickling drug and chemical manipulation of the haemoglobin helps manage the leg ulcer. The earlier studies30<\/sup> highlighted that there are no controlled clinical trials available to define the pharmacologic approach to cure the leg ulcer, which often goes undocumented. Therefore, as a preventive measure, the affected people should be made aware of the problems regarding leg ulcers. Recent studies appear to show topical and orally administered aloe vera preparations in patients with chronic venous leg ulcers may aid healing31<\/sup>.<\/p>\n

Dactylitis or hand-foot syndrome<\/strong><\/p>\n

Dactylitis affected 45% of the children by the age of 2 years32<\/sup>. Children are always at high risk of severe complications, if dactylitis occurs before 6 months of life. Episodes were significantly more common during colder months of the year and are related to intravascular sickling. Dactylitis commonly occurs in patients with homozygous hemoglobin S disease sickle cell-hemoglobin C disease or sickle cell-beta-thalassemia, but one of the case of dactylitis also reported33<\/sup> in sickle cell trait which is a very rare.<\/p>\n

Cassia occidentalis Linn. mast cell degranulation at a dose of 250 mg\/kg, showed dose dependent stabilizing activity towards human RBC, with is widely used in traditional medicine of India to treat a number of clinical conditions including allergy and inflammatory manifestations. C. occidentalis whole plant ethanolic extract inhibited mast cell degranulation stabilized HRBC membrane thereby alleviating immediate hypersensitivity besides showing anti oxidant activity34<\/sup>.<\/p>\n

Spleen<\/strong><\/p>\n

It has been reported35 <\/sup>that about 7% of the SCD patients possess acute splenic sequestration crisis. Frequent splenic infarcts were also reported to be a common episode in patients with SCD, which ultimately led to autosplenectomy36<\/sup>. Massive splenic infarction is a rare and unique complication of SCD, and for early diagnosis and treatment, physicians should be made aware of such a complication.<\/p>\n

Qiulirunfei extracta shows antiviral effects, and it is a good immune system enhancer, which should be explored as a potential therapeutic agent 37<\/sup>.<\/p>\n

Retinopathy<\/strong> (Eye Disease)<\/strong><\/p>\n

\u00a0<\/em>SCD children must check their eyes routinely to prevent vision-threatening complications38<\/sup>. Author studied 263 pediatric SCD patients and mentioned the Proliferative retinopathy (PR) was rare. But Six cases (8.2%) of PR were seen in the SC genotype, 1 case (0.6%) in the SS genotype, and no cases in the SB-Thalassemia genotype. SC genotype patients at the age of 9 years and 13 years of age for SS and SB-Thalassemia genotype patients should under go for retinopathy screening. Fuorescein angiography for Patients with an abnormal examination is also recommended38<\/sup>. Another study39<\/sup> of 55 adult SCD patients also reported severe sickle cell retinopathy is more common in SC genotype than the SS and SB genotypes. Proliferative retinopathy is more common in SC patients than SS and SB patients. Screening is useful in detecting sickle cell retinopathy.<\/p>\n

Stroke<\/strong><\/p>\n

Stroke is one of the major complications in patients with SCD40,41<\/sup>; however, it has been reported that the risk of stroke in childhood can be reduced through chronic blood transfusions42<\/sup>. Besides, prevention of the first stroke (primary prevention) was through the use of transcranial Doppler (TCD) was also reported. Previous studies42<\/sup> strongly emphasized that TCD must be performed in all children at 12-18 months of age to detect cerebral vasculopathy and prevention of stroke.<\/p>\n

From the literature, it is evident that there is a dearth of studies reporting results for acute stroke treatment for SCD patients, however, hydration and exchange transfusion were found to be often recommended practices.<\/p>\n

Acute Chest Syndrome (ACS)<\/strong><\/p>\n

ACS is a leading cause of hospitalization and death of children with SCD. ACS is an acute illness characterized by fever and respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest x ray. Younger children with greater blood and heat loss during surgery appear to be more prone to ACS. Splenectomy also seems to increase the risk of ACS. Inhaled nitric oxide and exchange transfusion therapy shown successful effects43<\/sup>. A major finding44<\/sup>of risk factor for the development of ACS is the hemoglobin genotype and the highest incidence is seen in Hb SS genotype (12.8 events\/100 personyears) and the lowest in Hb-S +\u03b2- thalassemia genotype (3.9 events\/100 person years)<\/p>\n

Oxygen<\/strong><\/p>\n

Arterial blood gas (ABG) analysis is used to measure the partial pressures of oxygen (PaO2) and carbon dioxide (pacO2)’ and the pH of an arterial sample. Earlier study documented45<\/sup> that Pulse oximetry is an accurate and effective non-invasive method for monitoring the arterial oxygen saturation in SCD. The lowest oxygen saturation to 86.5% +\/- 0.9% was observed during sleep. It has been reported46<\/sup> that in a fall in oxygen saturation was associated with a decrease in respiratory depth without a change in respiratory frequency. Oxygen saturation was lower during sleep than during wakefulness and that hypoxemia can be attributed to a fall in tidal volume is also reported in SCD patients.<\/p>\n

Renal Disease<\/strong><\/p>\n

Many renal structural and functional abnormalities reported in SCD. The prevention of the renal complications of SCD will required a cure for this genetic disorder is recommended47<\/sup>.\u00a0 The patients have impaired urinary concentrating ability, defects in urinary acidification and potassium excretion, and supranormal proximal tubular function. Recurrent hematuria is a relatively common problem in patients with SCD48<\/sup> and it is also observed in SCT. For the prevention of renal damage, routine screening of SCD patients is recommended.<\/p>\n

SCD In Males<\/strong><\/p>\n

Priapism<\/strong><\/p>\n

Priapism is one of the complications of SCD that receives very little attention but can be particularly bothersome for a large number of patients. If left untreated, irreversible fibrosis and impotency may occur. Other effects of priapism include pain, hospitalizations, and days missed from work, school, or other activities.\u00a0 Priapism is a rare urologic emergency in pediatric as well as in young population. It is a major consequence of SCD49.<\/sup> There are two types of priapism: low-flow and high-flow and the treatment is different for each type. Priapism is considered a\u00a0medical emergency, where the patient should receive appropriate treatment by a qualified medical practitioner as the functional recovery of the patient is dependent on early treatment.<\/p>\n

SCD In Females <\/strong><\/p>\n

Women with SCD experience multiple complications which can affect each and every organ system and are often worse in pregnant women. It is often noticed that more than one third of pregnancies in women with sickle syndromes terminate in abortion, stillbirth, or neonatal death. Past studies50<\/sup> report that over seventy-two thousand Americans were homozygous for the sickle cell gene and 2 million were carriers.<\/p>\n

Pregnancy<\/strong><\/p>\n

Earlier longitudinal studies51<\/sup> reported that the first pregnancy loss among SS women was much higher at 22% as compared to SC women at 12%. Similarly the percentage of foetal loss was high in SS women (19.2%) in comparison to SC women (8.9%). The specific finding50<\/sup> were that the prenatal mortality rate was very high in SS women than in SC women. The midterm\/stillbirth death was negligible in SC women as compared to SS women. Overall it has been concluded that pregnancy loss is more in among SS women as compared to SC women.<\/p>\n

One of the study reported52<\/sup> that medicinal plant use is common among the Brou, Saek and Kry ethnic groups of South Asia to facilitate childbirth, alleviate menstruation problems, assist recovery after miscarriage, mitigate postpartum haemorrhage, aid postpartum recovery, and for use in infant care.<\/p>\n

Mortality and Morbidity<\/strong><\/p>\n

With the developments in science and technology, the lifespan of the mother and child has increased considerably. However, mortality and morbidity was reported to be higher in SS women as compared to AA women53<\/sup>. One of the study reported54<\/sup> that with a proper combination of obstetrician and hematologist care, and using latest laboratory techniques there can be marked decrease in the maternal and perinatal morbidity rates and mortality in the pregnant SS women.<\/p>\n

Infection<\/strong><\/p>\n

Apart from other complications, infection is a major complication in SCD and secondary infection, such as pulmonary infection has been extensively reported55<\/sup>. Although special preventive measures against different infections exist in addition to routine immunizations; often treatment regimens are based on local formularies and antibiotic sensitivity tests. The single most common cause of death in children with SCD is Streptococcus pneumoniae sepsis56,57<\/sup>. However, it has been observed that proper vaccination and course of prophylactic antibiotics can prevent pneumococcal disease.<\/p>\n

Scientific research on the healing properties and bioactivity of natural compounds, especially of plant origin, has been extensive particularly in the Western world58<\/sup>. However, a rich heritage of floral biodiversity is found in developing countries, which needs to be explored. A number of medicinal plants (of Amaryllidaceae and Hyacinthaceae families) have particular uses as disinfectants and anti-inflammatory agents, although there is still a lack of scientific research regarding their unique pharmacological compounds. Allium sativum (garlic) extract has broad-spectrum antimicrobial activity against many genera of bacteria and fungi. Because many of the microorganisms susceptible to garlic extract are medically significant, garlic holds a promising position as a broad-spectrum therapeutic agent, especially in treatment of SCD59<\/sup>.<\/p>\n

Psychological Aspect of SCD<\/strong><\/p>\n

Depression and Anxiety<\/strong><\/p>\n

Little is known about the impact of depression and anxiety on SCD adults60<\/sup>. An epidemiological study showed that 27.6% SCD patients were depressed and 6.5% had one or the other anxiety disorder. Depressed subjects had pain on significantly more days than non-depressed subjects. It has been concluded that depression and anxiety predicted more daily pain and poorer physical and mental quality-of-life in adults with SCD, and accounted for more of the variance in all domains of quality-of-life than hemoglobin type. Cognitive behaviour therapy (CBT) is commonly used to treat, depression and anxiety.<\/p>\n

Medicinal plants (Bacopa monniera and Panax quniquefolium have significant adaptogenic properties) can be used against mixed anxiety-depressive disorder (MAD)61<\/sup>. The authors reported that extracts of these plants can be used as a potent therapeutic agent in treating MAD. Other study reported62<\/sup> that Ocimumn sanctum is a promising anxiolytic agent, which may be useful in treatment of generalized anxiety disorder; however, more confirmatory studies are necessary.<\/p>\n

Treatments for SCD<\/strong><\/p>\n

Medicinal Plants<\/strong><\/p>\n

above section shows the utility of medicinal plants for possible use in the treatment of SCD. However, the knowledge that exists today needs confirmation through further systematic research investigation. Although the efforts by many scientists are underway, the exploration of medicinal plants for efficient treatment option shows promising future due to its low cost and no to negligible side effects. \u00a0\u00a0\u00a0\u00a0<\/strong><\/p>\n

Vaccination<\/strong><\/p>\n

Patients with SCD are susceptible to bacterial infections (Streptococcus pneumoniae63<\/sup>), especially those caused by encapsulated organisms. The efficacy of oral penicillin prophylaxis against pneumococcal infections has been well established and is now recommended from 3 months of age64<\/sup>. The high incidence and severity of bacterial infections in children with SCD justify prevention efforts by antibiotic prophylaxis and vaccination.65<\/sup><\/p>\n

Hydroxyurea (HU)<\/strong><\/p>\n

Pediatric studies have shown that HU can be safely used in children as well as in adults for improving the QOL66<\/sup> who already suffer from moderate-to-severe SCD. The improvement in laboratory parameters has also been reported67<\/sup> that suggests the beneficial use of HU in preventing acute clinical complications of SCD in children as well as in adults. \u00a0In another study68<\/sup> regarding the safety and efficiency of HU, it was found that HU increased the fetal Hb production in previously ill children with SCD68<\/sup> and decreased morbidity from vaso-occlusive complications in patients with SCD69<\/sup>. After the treatment for 32 months, it was observed that HU increased the level of Hb F in all children except one, who took 9 months. There was drastic reduction in pain crises and hematopoietic complications were not observed. In conclusion it was stressed that the use of HU is effective in reducing painful events in children with SCD. Results of studies70<\/sup>, report that use of HU reduced the overall mortality rate by almost 40%. The survival was attributed to HbF levels and frequency of vaso-occlusive events.<\/p>\n

Cognitive Behaviour Therapy (CBT)<\/strong><\/p>\n

CBT is a type of psychotherapeutic treatment that helps patients to understand the thoughts and feelings that influence behaviours. It has been reported that it is most effective in the management of SCD pain, which also reduces the psychological distress and helps to improve coping71<\/sup>. The CBT is economically efficient and is most cost effective during the first 6 months after the intervention. It has been recommended that CBT should be integrated as a part of the normal care available to the SCD patients and should be regularly offered every 6.<\/p>\n

Bone Marrow Transplant (BMT)<\/strong><\/p>\n

Currently it is widely accepted that the only curative therapy for SCD is BMT72<\/sup>, which is rarely applied. The overall survival and disease free condition is greater than 80% following matched sibling BMT for SCD. Unfortunately, most patients with SCD do not have a suitable human lymphocyte antigen-matched sibling donor. So to increases the possibilities of match donor, several groups are beginning to explore the use of alternative sources of stem cells such as haploidentical donors and umbilical cord cell blood72<\/sup>. It has been reported that the cost of BMT was significantly less in India as compared to western countries72<\/sup>. In the support of BMT, the study73 <\/sup>stressed the need to develop more transplant centers with adequately trained personnel in India. Though the cost of BMT is less in India as compared to other countries but in India the SCD patients are mostly tribals and are from economically backward classes and the cost of the treatment is beyond their reach.<\/p>\n

Gene <\/strong>Replacement<\/strong> Therapy<\/strong><\/p>\n

It is a process whereby the defective gene of the sickle hemoglobin is replaced with normal gene. Gene therapy for SCD, is the ultimate cure for the disorder, but is not imminent. Hence, research efforts need to be diverted for exploring further in the realm of gene replacement therapy for improving the problem of SCD.<\/p>\n

Genetic Counseling<\/strong><\/p>\n

The importance of genetic counseling is gaining momentum in fight against SCD74<\/sup>. The need for providing sufficient information of SCD especially for students has been recommended in addition to genetic counseling. One of the problems reported elsewhere75,76<\/sup> observed that the SCD patients participating in ethnographic survey while undergoing genetic counseling had a great concern about the confidentiality of their genetic information in public domain. Patients further suggested that the ethical principle of confidentiality needs to be seen as a human right and public health issue.<\/p>\n

Conclusions<\/strong><\/p>\n

SCD a common genetic haemoglobin disorder has been reported worldwide with the developing countries having significantly higher prevalence rates. A comprehensive and reliable data for prevalence, however, is not available for Indian context and majority of children die undiagnosed, untreated or under treated. From the literature, it is evident that the early diagnosis and treatment of newborns can reduce many complications and increase life expectancy and quality of life of an SCD patient. Furthermore, numerous studies have reported effective use of medicinal plants for managing different complications of SCD patients. Specifically, the medicinal plants have been used for antisickling (Bombax pentadrum, Ficus capensis, Parinari mobola and Ziziphus mucronata), IDA (Sorghum bicolor (L.), Pfaffia Paniculata (PP), pain (Siculine syrup (a traditional herbal remedy), ulcers (Aloe vera), Dactylitis (Cassia occidentalis Linn.), spleen (Qiulirunfei extracta), infection (Amaryllidaceae and Hyacinthaceae families, Allium sativum – garlic) and depression and anxiety (Bacopa monniera and Panax quniquefolium). Furthermore, the treatment options most widely used are antibiotics, Hydroxyurea, Cognitive behaviour therapy, Bone Marrow Transplant, Gene replacement therapy, Genetic counselling, etc. In conclusion, this review indicates that variety of medicinal plants have been utilized throughout the world to address different physiological and other complications of SCD sufferers. However, the knowledge of the use of these agents is in nascent stage and needs further investigations for using these medicinal plants as regular treatment option.<\/p>\n

Acknowledgements<\/strong><\/p>\n

The authors acknowledge the help from PG Department of Microbiology, R.T.M. Nagpur University, Nagpur.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Balgir, R. S. \u201cPhenotypic diversity of sickle cell disorders with special emphasis on public health genetics in India.\u201d Curr<\/em>. <\/em>Sci, <\/em>98: 1096\u20131102 (2010).<\/li>\n
  2. Ingram, V. M. \u201cGene mutation in human Hemoglobin: The clinical difference between normal and sickle cell haemoglobin.\u201d Nature, 180: 326-328 (1957).<\/li>\n
  3. Balgir, R. S. \u201cScenario of haemoglobin variants in Central-East coast of India.\u201d Curr<\/em>. <\/em>Sci,<\/em> 90: 1651 (2006).<\/li>\n
  4. Angastiniotis, M. A. and Modell, B. \u201cGlobal epidemiology of haemoglobin disorders.\u201d N.Y. Acad. Sci, 850: 251\u201369 (1998).<\/li>\n
  5. Vichinsky, Hurst, D. Earles, A. \u201cNewborn screening for sickle cell disease: effect on mortality.\u201d Pediatrics, 81: 749\u201355 (1988).<\/li>\n
  6. Kate, S. L. \u201cHealth problems of tribal population groups from the state of Maharashtra.\u201d Indian J. Med. Sci, 55: 99\u2013108 (2001).<\/li>\n
  7. Mpiana, P. T. Mudogo, V. Tshibangu, D. S. and Kitwa, E. K. \u201cAntisickling activity of anthocyanins from Bombax pentadrum, Ficus capensis and Ziziphus mucronata: photodegradation effect.\u201d J Ethnopharmacol, 120 :413-8 (2008).<\/li>\n
  8. Akojie, F. O. and Fung, L. W. \u201cAntisickling activity of hydroxybenzoic acids in Cajanus cajan.\u201d Planta Med,\u00a0 58: 317-20 (1992).<\/li>\n
  9. Ibrahim, H. Sani, F. S. Danladi, B. H. and Ahmadu, A. A. \u201cPhytochemical and antisickling studies of the leaves of Hymenocardia acida Tul (Euphorbiaceae).\u201d Pak J Biol Sci,\u00a0 10: 788-91 (2007).<\/li>\n
  10. Moody, J. O. Ojo, O. Omotade, O. and Adeyemo, A. A. \u201cAnti-sickling potential of a Nigerian herbal formula (ajawaron HF) and the major plant component (Cissus populnea L. CPK).\u201d Phytother Res, 17: 1173-6 (2003).<\/li>\n
  11. Steinberg, M. H. and Rodgers, G. P. \u201cPathophysiology of sickle cell disease: role of cellular and genetic modifiers.\u201d Semin Hematol, 38: 299-306 (2001).<\/li>\n
  12. Buchanan, G. Vichinsky, E. Krishnamurti, L. et al. \u201cSevere sickle cell disease–pathophysiology and therapy.\u201d Biol Blood Marrow Transplant, 1: 64\u20137 (2010).<\/li>\n
  13. Godeau, B. Noel, V. Habibi, A. et al. \u201cSickle cell disease in adults: which emergency care by the internists?.\u201d Revue de Medecine Interne, 22: 440\u201351 (2001).<\/li>\n
  14. Ray, D. Deshmukh, P. Goswami, K. et al. \u201cAntioxidant vitamin levels in sickle cell disorders.\u201d Natl Med J India, 20: 11\u20133 (2007).<\/li>\n
  15. Takasu, J. Uykimpang, R. Sunga, M. A. and Amagase, H. \u201cAged garlic extract is a potential therapy for sickle-cell anemia.\u201d J Nutr, 136 :803S-805S (2006).<\/li>\n
  16. Ohnishi, S. T. and Ohnishi, T. \u201cIn vitro effects of aged garlic extract and other nutritional supplements on sickle erythrocytes.\u201d J Nutr, 131: 1085S-92S (2001).<\/li>\n
  17. Powars, D. R. \u201cNatural history of sickle cell disease\u2014the first ten years.\u201d Semin Hematol, 12: 267 (1975).<\/li>\n
  18. Malay, B. Mukherjee, R. R. and Gangakhedkar, \u201cPhysical growth of children with sickle cell disease\u201d Indian Journal of Human Genetics, 10: 70-72 ( 2004).<\/li>\n
  19. Barden, E. M. Kawchak, D. A.\u00a0 Ohene-Frempong, K. Stallings V. A. et al. \u201cBody composition in children with sickle cell disease.\u201d American Journal of Clinical Nutrition, 76: 218-225 (2002).<\/li>\n
  20. Mohanty, D. Mukherjee, M. B. et al. \u201cSickle cell disease in India.\u201d Current Opinion in Hematology, 9: 117-122 (2000).<\/li>\n
  21. Mohanty, D. Mukherjee, M. B. Colah, R.B. et al. \u201cIron deficiency anaemia in sickle cell disorders in India.\u201d Indian J Med Res, 127: 366\u20139 (2008).<\/li>\n
  22. King, L. Reid, M. and Forrester, T. E. \u201cIron deficiency anaemia In Jamaican children, aged 1-5 years, with sickle cell disease.\u201d West Indian Med J, 54: 292\u201396 (2005).<\/li>\n
  23. Oladiji, A. T. Jacob, T. O. and Yakubu, M. T. \u201cAnti-anaemic potentials of aqueous extract of Sorghum bicolor (L.) moench stem bark in rats.\u201d J Ethnopharmacol, 111: 651-6 (2007).<\/li>\n
  24. Ballas, S. K. \u201cHydration of sickle erythrocytes using a herbal extract (Pfaffia paniculata) in vitro.\u201d Br J Haematol, 111: 359-62 (2000).<\/li>\n
  25. Platt, O. S. Thorington, B. D. and Brambilla, D. J. \u201cPain in sickle cell disease. Rates and risk factors.\u201d N Engl J Med, 25: 11-6 (1991).<\/li>\n
  26. Jerrell, J. M. Tripathi, A. and Stallworth, J. R. \u201cPain management in children and adolescents with sickle cell disease.\u201d Am J Hematol, 86: 82-4 (2011).<\/li>\n
  27. Kwanashie, H. O. Ejiofor, J. I, Abdu-Aguye, I. Nkweteyim, J. N. \u201cPharmacological studies on siculine syrup. II: effects on smooth, skeletal and cardiovascular muscle preparations.\u201d Phytother Res, 23: 236-40 (2009).<\/li>\n
  28. Isoa, E. M. \u201cCurrent trends in the management of sickle cell disease: an overview.\u201d Benin<\/em> Journal of Postgraduate Medicine, <\/em>11: 50-64 (2009).<\/li>\n
  29. Chung, C. Cackovic, M. and Kerstein, M. D. \u201cLeg ulcers in patients with sickle cell disease.\u201d Adv Wound Care,<\/em> 9: 46\u201350 (1996).<\/li>\n
  30. Eckman, J. R. \u201cLeg ulcers in sickle cell disease.\u201d Hematol Oncol Clin North Am, 10: 1333\u201344 (1996).<\/li>\n
  31. Atherton, P. \u201cAloe vera: magic or medicine?\u201d Nurs Stand, 12: 49-52 (1998).<\/li>\n
  32. Stevens, M. C. Padwick, M. and Serjeant, G. R. \u201cObservations on the natural history of dactylitis in homozygous sickle cell disease.\u201d Clin Pediatr (Phila), 5: 311-7 (1981).<\/li>\n
  33. Jadavji, T. and Prober, C. G. \u201cDactylitis in a child with sickle cell trait.\u201d Can Med Assoc J, 132: 814-5 (1985).<\/li>\n
  34. Sreejith, G. Latha, P. G. Shine, V. J. Anuja, G. I. \u201cAnti-allergic, anti-inflammatory and anti-lipidperoxidant effects of Cassia occidentalis Linn. Indian\u201d J Exp Biol, 48: 494-8 (2010).<\/li>\n
  35. Al-Hawsawi, Z. M. and Ismail, G. A. \u201cAcute splenic sequestration crisis in children with sickle cell disease.\u201d Saudi Med J, 22: 1076\u20139 (2001).<\/li>\n
  36. Jama, A. H. Salem, A. H. and Dabbous, I. A. \u201cMassive splenic infarction in Saudi patients with sickle cell anemia: a unique manifestation.\u201d Am J Hematol, 69: 205\u20139 (2002).<\/li>\n
  37. Li, X. and Li, X. M. \u201cEffects of Qiulirunfei extracta on immunological function and influenza virus in mice.\u201d Zhong Yao Cai, 31: 561-4 (2008).<\/li>\n
  38. Gill, H. S. and Lam, W. C. \u201cA screening strategy for the detection of sickle cell retinopathy in pediatric patients.\u201d Can J Ophthalmol, 43:188-91 (2008).<\/li>\n
  39. Tran, T. H. Mekinian, A. Godinaud, M. and Rose, C. \u201cScreening for sickle cell disease retinopathy in the north of France.\u201d J Fr Ophtalmol, 31: 987-92 (2008).<\/li>\n
  40. Mehta, S. H. and Adams, R. J. \u201cTreatment and prevention of stroke in children with sickle cell disease.\u201d Current treatment options in neurology, 8: 503\u201312 (2006).<\/li>\n
  41. Bernaudin, F. and Verlhac, S. \u201cStroke prevention in sickle-cell disease: results, hurdles and future perspectives.\u201d Bulletin de l’Academie Nationale de Medecine, 192: 1383\u201393 (2008).<\/li>\n
  42. Adams, R. J. \u201cTCD in sickle cell disease: an important and useful test.\u201d Pediatr Radiol, 35: 229\u201334 (2005).<\/li>\n
  43. Laurie, G. A. \u201cAcute chest syndrome in sickle cell disease.\u201d Intern Med J, 40 : 372-6 (2010).<\/li>\n
  44. Castro, O. Brambilla, D. J. Thorington, B. et al. \u201cThe acute chest syndrome in sickle cell disease: Incidence and risk factors.\u201d Blood, 84: 643-9 (1994).<\/li>\n
  45. Weston Smith, S. G. Glass, U. H. Acharya, J. and Pearson, T. C. \u201cPulse oximetry in sickle cell disease.\u201d Clin Lab Haematol,11: 185-8 (1989).<\/li>\n
  46. Castele, R. J. Strohl, K. P. Chester, C. S. Brittenham, G. M. and Harris, J. W. \u201cOxygen saturation with sleep in patients with sickle cell disease\u201d Arch Intern Med,146 :722-5 (1986).<\/li>\n
  47. Ataga, K. I. and Orringer, E. P. \u201cRenal abnormalities in sickle cell disease.\u201d Am J Hematol, 63 :205-11(2000).<\/li>\n
  48. Allon, M. \u201cRenal abnormalities in sickle cell disease.\u201d Arch Intern Med, 150 :501-4 (1990).<\/li>\n
  49. Sibai, H. Sakoute, A. and Yaakoubi, M. et al. \u201cPediatric priapism associated with pulmonary infection.\u201d Ann Urol (Paris),37: 143-5 (2003).<\/li>\n
  50. Dauphin-McKenzie, N. Gilles, J. M. Jacques, E. et al. \u201cSickle cell anemia in the female patient.\u201d Obstet Gynecol Surv, 61: 343\u201352 (2006).<\/li>\n
  51. Milner, P.F. Jones, B. R. and D\u00f6bler, J. \u201cOutcome of pregnancy in sickle cell anemia and sickle cell-hemoglobin C disease. An analysis of 181 pregnancies in 98 patients, and a review of the literature.\u201d Am J Obstet Gynecol, 138: 239\u201345 (1980).<\/li>\n
  52. de Boer, H. Lamxay, V. \u201cPlants used during pregnancy, childbirth and postpartum healthcare in Lao PDR: a comparative study of the Brou, Saek and Kry ethnic groups.\u201d J Ethnobiol Ethnomed, 8: 5-25 (2009).<\/li>\n
  53. McLaughlin, B. N. Martin, R. W. and Morrison, J. C. \u201cClinical management of sickle cell hemoglobinopathies during pregnancy.\u201d Clin Perinatol, 12: 585\u201397 (1985).<\/li>\n
  54. Koshy, M. and Burd, L. \u201cManagement of pregnancy in sickle cell syndromes.\u201d Hematol Oncol Clin North Am, 5: 585\u201396 (1991).<\/li>\n
  55. Lionnet, F. Bachmeyer, C. Sloma, I. et al. \u201cTuberculosis in adult patients with sickle cell disease.\u201d J Infect, 55: 439\u201344 (2007).<\/li>\n
  56. Leikin, S. L. Gallagher, D. Kinney, T. et al. \u201cMortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease.\u201d Pediatrics,\u00a0 84: 500-8 (1989).<\/li>\n
  57. Gill, F. M. Sleeper, L. A. Weiner, S. J. et al. \u201cClinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative study of sickle cell disease.\u201d Blood, 86: 776-83 (1995).<\/li>\n
  58. Louw, C. A. Regnier, T. J. and Korsten, L. \u201cMedicinal bulbous plants of South Africa and their traditional relevance in the control of infectious diseases.\u201d J Ethnopharmacol, 82:147-54 (2002).<\/li>\n
  59. Adetumbi, M. A, Lau, B. H. \u201cAllium sativum (garlic)–a natural antibiotic.\u201d Med Hypotheses, 12: 227-37 (1983).<\/li>\n
  60. Levenson, J. L. Donna, M. D. McClish, K. et al. \u201cDepression and anxiety in adults with sickle cell disease. The pisces project.\u201d Psychosom Med, 70: 192\u20136 (2008).<\/li>\n
  61. Chatterjee, M. Verma, P. and Palit, G. \u201cComparative evaluation of Bacopa monniera and Panax quniquefolium in experimental anxiety and depressive models in mice.\u201d Indian J Exp Biol, 48: 306-13 (2010).<\/li>\n
  62. Bhattacharyya, D. Sur, T. K. Jana, U. and Debnath, P. K. \u201cControlled programmed trial of Ocimum sanctum leaf on generalized anxiety disorders.\u201d Nepal Med Coll J, 10: 176-9 (2008).<\/li>\n
  63. Hardie, R. King, L. Fraser, R. and Reid, M. \u201cPrevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screening.\u201d Ann Trop Paediatr, 3: 197-202 (2009).<\/li>\n
  64. Mehta, S. R. Afenyi-Annan, A. Byrns, P. J. and Lottenberg, R. \u201cOpportunities to improve outcomes in sickle cell disease.\u201d Am Fam Physician, 74: 303-10 (2006).<\/li>\n
  65. Lepage, P. Dresse, M. F. Forget, P. Schmitz, V. and Hoyoux, C. \u201cInfections and antibiotic prophylaxis in sickle cell disease.\u201d Rev Med Liege, 3: 145-8 (2004).<\/li>\n
  66. Ballas, K. Dove, G. J. Charache, S. et al. \u201cHydroxyurea and sickle cell anemia: effect on quality of life.\u201d Health and Quality of Life Outcomes, <\/em>4: 59 (2006).<\/li>\n
  67. Thornburg, C. D. Dixon, Burgett, S. et al. \u201cA pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia.\u201d Pediatric Blood<\/em> & Cancer,<\/em> 52: 609\u201315 (2009).<\/li>\n
  68. de Montalembert, M. Belloy, M. Bernaudin, F. et al. \u201cThree-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.\u201d Journal of Pediatric<\/em> Hematology\/Oncology,<\/em> 19: 313\u2013318 (1997).<\/li>\n
  69. Hoppe, C. Vichinsky, E. Quirolo, K. et al. \u201cUse of hydroxyurea in children ages 2 to 5 years with sickle cell disease.\u201d Journal of Pediatric<\/em> Hematology\/Oncology,<\/em> 22: 330\u2013334 (2000)<\/li>\n
  70. Steinberg, M. H. Barton, F. Castro, O. et al. \u201cEffect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.\u201d J Am Med Assoc, 289: 1645\u201351 (2003).<\/li>\n
  71. Thomas, V. J. Gruen, R. and Shu, S. \u201cCognitive-behavioural therapy for the management of sickle cell disease pain: identification and assessment of costs.\u201d Ethnic health,<\/em> 6: 59\u201367 (2001).<\/li>\n
  72. Chandy, M. \u201cStem cell transplantation in India.\u201d Bone Marrow Transplant, 42: S81\u2013S84 (2008).<\/li>\n
  73. Bola\u00f1os-Meade, J. and Brodsky, R. A. \u201cBlood and marrow transplantation for sickle cell disease: overcoming barriers to success.\u201d Curr Opin Oncol, 21: 158\u201361 (2009).<\/li>\n
  74. Moronkola, O. A. and Fadairo, R. A. \u201cUniversity students in Nigeria: knowledge, attitude toward sickle cell disease, and genetic counseling before marriage.\u201d International quarterly of community health education, 26: 85\u201393 (2006).<\/li>\n
  75. Diniz, D. and Guedes, C. \u201cConfidentiality, genetic counselling and public health: a case study.\u201d Cadernos de Saude Publica, 21: 747\u201355 (2005).<\/li>\n
  76. Opawoye, A. D. \u201cCommunicating basic genetics to patients with sickle-cell disease.\u201d Eastern Mediterranean Health Journal, 5: 1178\u20131182 (1999).<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction Human genetic diversity poses a great challenge to community […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"class_list":["post-1728","post","type-post","status-publish","format-standard","hentry","category-vol4no1"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/1728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=1728"}],"version-history":[{"count":4,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/1728\/revisions"}],"predecessor-version":[{"id":12947,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/1728\/revisions\/12947"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=1728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=1728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=1728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}